Enzymotec Ltd. Quick Ratio (ENZY) starting from the fourth quarter 2016 to fourth quarter 2015, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Enzymotec Ltd.  (ENZY)

Enzymotec Ltd.'s Quick Ratio

ENZY's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Enzymotec Ltd.'s Cash & cash equivalent grew by 121.99 % in the Q4 2016 sequentially, while Current Liabilities decreased, this led to improvement in Enzymotec Ltd.'s Quick Ratio to 11.47, above Enzymotec Ltd. average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 83 other companies have achieved higher Quick Ratio than Enzymotec Ltd. in fourth quarter 2016. While Quick Ratio total ranking in the fourth quarter 2016 has deteriorated compared to the prior quarter from 760 to 765.

Explain Quick Ratio?
How much Cash & cash equivalents ENZY´s has?
What are ENZY´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ENZY Quick Ratio (Dec 31 2016)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2015)
Q4
Y / Y Current Liabilities Change -6.64 % -18.5 % -18.5 % -18.5 % 5.29 %
Y / Y Cash & cash equivalent Change 1.64 % -2.93 % -2.93 % -2.93 % 24.84 %
Quick Ratio MRQ 11.47 3.04 3.04 3.04 10.53
ENZY's Total Ranking # 765 # 760 # 772 # 700 # 808
Seq. Current Liabilities Change -41.08 % 0 % 0 % 58.46 % -48.57 %
Seq. Cash & cash equivalent Change 121.99 % 0 % 0 % -54.22 % 112.02 %



Quick Ratio fourth quarter 2016 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 84
Healthcare Sector # 298
Overall Market # 765


Quick Ratio Statistics
High Average Low
3.04 2.8 2.56
(Dec 31 2016)   (Dec 31 2015)




Financial Statements
Enzymotec Ltd.'s Current Liabilities $ 5 Millions Visit ENZY's Balance sheet
Enzymotec Ltd.'s Cash & cash equivalent $ 60 Millions Visit ENZY's Balance sheet
Source of ENZY's Sales Visit ENZY's Sales by Geography


Cumulative Enzymotec Ltd.'s Quick Ratio

ENZY's Quick Ratio for the trailling 12 Months

ENZY Quick Ratio

 (Dec 31 2016)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2015)
12 Months
Y / Y Current Liabilities TTM Growth -16.76 % -15.17 % 26.35 % 123.67 % 619.41 %
Y / Y Cash & cash equivalent TTM Growth -1.04 % 7.11 % 36.86 % 88.67 % 201.49 %
Quick Ratio TTM 4.43 4.35 4.11 3.91 3.72
Total Ranking TTM # 3396 # 365 # 365 # 364 # 0
Seq. Current Liabilities TTM Growth -1.15 % -5.88 % -5.56 % -5.26 % 0.74 %
Seq. Cash & cash equivalent TTM Growth 0.69 % -0.58 % -0.58 % -0.57 % 8.98 %

Quick ratio ranking by company, industry and sector >> Back to ENZY Financial Strength Comparisons >> Go to Compare ENZY Quick Ratio to its Competitors

On the trailing twelve months basis ENZY Cash & cash equivalent improved by 1.64 % in Q4 2016 year on year, while Current Liabilities plummeted to $5 millions, this led to increase in in Enzymotec Ltd.'s Quick Ratio to 4.43, above ENZY average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 46 other companies have achieved higher Quick Ratio than Enzymotec Ltd.. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2016 from 365 to 3396.

Explain Quick Ratio?
How much Cash & cash equivalents ENZY´s has?
What are ENZY´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 47
Healthcare Sector # 448
Within the Market # 3396


trailing twelve months Quick Ratio Statistics
High Average Low
3.04 2.75 2.56
(Dec 31 2016)   (Dec 31 2015)




Companies with similar Quick Ratio in the quarter ending Dec 31 2016, within Biotechnology & Pharmaceuticals Industry Quick RatioDec 31 2016 MRQ Cash & cash equivalentDec 31 2016 MRQ Current Liabilities
Atara Biotherapeutics Inc   26.43 $ 255.682  Millions$ 9.675  Millions
Allena Pharmaceuticals Inc.  22.48 $ 73.057  Millions$ 3.250  Millions
Fennec Pharmaceuticals Inc   19.53 $ 7.852  Millions$ 0.402  Millions
Biocardia Inc   18.73 $ 21.352  Millions$ 1.140  Millions
Repligen Corp  17.15 $ 141.780  Millions$ 8.268  Millions
Editas Medicine Inc   16.67 $ 372.246  Millions$ 22.335  Millions
Cellular Biomedicine Group Inc   16.60 $ 39.252  Millions$ 2.364  Millions
Crispr Therapeutics Ag  14.34 $ 315.520  Millions$ 21.998  Millions
Adverum Biotechnologies Inc   14.15 $ 222.170  Millions$ 15.704  Millions
Vivosim Labs Inc   13.83 $ 62.091  Millions$ 4.490  Millions
Voyager Therapeutics Inc   12.64 $ 174.418  Millions$ 13.802  Millions
Aerie Pharmaceuticals Inc   12.06 $ 233.662  Millions$ 19.371  Millions
Qiagen N v   11.80 $ 833.744  Millions$ 70.627  Millions
Cidara Therapeutics Inc   11.74 $ 104.619  Millions$ 8.909  Millions
Aceragen Inc   11.66 $ 109.014  Millions$ 9.353  Millions
Immunitybio inc   11.57 $ 198.921  Millions$ 17.187  Millions
Brainstorm Cell Therapeutics inc   11.56 $ 9.990  Millions$ 0.864  Millions
Enzymotec Ltd.  11.47 $ 60.327  Millions$ 5.261  Millions
Genocea Biosciences Inc   10.23 $ 63.362  Millions$ 6.192  Millions
Spark Therapeutics Inc   9.87 $ 296.166  Millions$ 29.998  Millions
Bluebird Bio Inc   9.45 $ 704.378  Millions$ 74.533  Millions
Dbv Technologies S a   8.84 $ 270.630  Millions$ 30.603  Millions
Acceleron Pharma inc  8.65 $ 139.690  Millions$ 16.149  Millions
Eiger Biopharmaceuticals Inc   8.42 $ 59.936  Millions$ 7.119  Millions
Protara Therapeutics Inc  8.13 $ 41.317  Millions$ 5.079  Millions
Viskase Holdings inc   8.13 $ 7.639  Millions$ 0.940  Millions
Momenta Pharmaceuticals inc   7.94 $ 353.151  Millions$ 44.459  Millions
Sangamo Therapeutics Inc   7.77 $ 142.535  Millions$ 18.336  Millions
Aevi Genomic Medicine, Inc.  7.14 $ 39.838  Millions$ 5.583  Millions
La Jolla Pharmaceutical Company  6.74 $ 65.726  Millions$ 9.758  Millions

Date modified: 2026-09-02T18:56:07+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.